Zobrazeno 1 - 10
of 393
pro vyhledávání: '"Anthony, Gonçalves"'
Autor:
Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 8 (2024)
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimu
Externí odkaz:
https://doaj.org/article/be397a2c9d104c41b010a59bc9500941
Autor:
Javier Cortes, Eric P Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalves, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells)
Externí odkaz:
https://doaj.org/article/42c035448af94e8fbfc51bd921ef67f3
Autor:
Gilles Houvenaeghel, Alexandre deNonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Emmanuelle Charaffe, Aurélie Jalaguier, Marie Bannier, Agnès Tallet, Frédéric Viret, Anthony Gonçalves
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Aim We investigated the pathologic complete response rates (pCR) and survival outcomes of early breast cancer patients who underwent neoadjuvant chemotherapy (NAC) over 14 years at a French comprehensive cancer center and reported pCR and su
Externí odkaz:
https://doaj.org/article/45320565ca9343be958e19208d8fe6d4
Autor:
Gilles Houvenaeghel, Monique Cohen, Anthony Gonçalves, Axel Berthelot, Marie Pierre Chauvet, Christelle Faure, Jean Marc Classe, Eva Jouve, Laura Sabiani, Marie Bannier, Louis Tassy, Marc Martino, Agnès Tallet, Alexandre de Nonneville
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundElderly breast cancer (BC) patients have been underrepresented in clinical trials whereas ~60% of deaths from BC occur in women aged 70 years and older. Only limited data are available on the prognostic impact of age according to treatment,
Externí odkaz:
https://doaj.org/article/525d651b87a642eeb6f33c517c4b41db
Autor:
Ondine Dufour, Gilles Houvenaeghel, Jean-Marc Classe, Monique Cohen, Christelle Faure, Chafika Mazouni, Marie-Pierre Chauvet, Eva Jouve, Emile Darai, Anne-Sophie Azuar, Pierre Gimbergues, Anthony Gonçalves, Alexandre de Nonneville
Publikováno v:
Breast, Vol 68, Iss , Pp 163-172 (2023)
Background: There is a scarcity of data exploring early breast cancer (eBC) in very young patients. We assessed shared and intrinsic prognostic factors in a large cohort of patients aged ≤35, compared to a control group aged 36 to 50. Methods: Pati
Externí odkaz:
https://doaj.org/article/121ebed073b543aab7c81b276d25f578
Autor:
Anne Madroszyk, Gwenaelle Gravis, Laurent Gorvel, Daniel Olive, Christophe Zemmour, Philippe Rochigneux, Anthony Gonçalves, Mathilde Beaufils, Vincent Amodru, Manuel Tejeda, Jean Marie Boher, Brice Chanez, Anne Sophie Chrétien, Damien Bruyat, Roxane Mari, Thomas Cuny, Aaron E Lisberg, Louis Tassy, Frederic Castinetti
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Dysthyroidism (DT) is a common toxicity of immune checkpoint inhibitors (ICIs) and prior work suggests that dysthyroidism (DT) might be associated with ICI efficacy.Patients and methods ConSoRe, a new generation data mining solution, was u
Externí odkaz:
https://doaj.org/article/b975d57f3e8b46958dd86ac07ec93343
Autor:
Adeolu Z. Ogunleye, Chayanit Piyawajanusorn, Anthony Gonçalves, Ghita Ghislat, Pedro J. Ballester
Publikováno v:
Advanced Science, Vol 9, Iss 24, Pp n/a-n/a (2022)
Abstract Doxorubicin is a common treatment for breast cancer. However, not all patients respond to this drug, which sometimes causes life‐threatening side effects. Accurately anticipating doxorubicin‐resistant patients would therefore permit to s
Externí odkaz:
https://doaj.org/article/23bededaf5204aaf9bc65e9fb73c41aa
Autor:
Renaud Sabatier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Jihane Pakradouni, José Adelaide, Magali Provansal, Maria Cappiello, Frédérique Rousseau, Max Chaffanet, Daniel Birnbaum, Emilie Mamessier, Anthony Gonçalves, François Bertucci
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionThe poor prognosis of ovarian carcinoma (OvC) is due to the advanced stage at diagnosis, a high risk of relapse after first-line therapies, and the lack of efficient treatments in the recurrence setting. Circulating tumor DNA (ctDNA) anal
Externí odkaz:
https://doaj.org/article/e8ca0d11810341ec999c93a85f969100
Autor:
François Bertucci, Anthony Gonçalves, Arnaud Guille, José Adelaïde, Séverine Garnier, Nadine Carbuccia, Emilien Billon, Pascal Finetti, Patrick Sfumato, Audrey Monneur, Christophe Pécheux, Martin Khran, Serge Brunelle, Lenaïg Mescam, Jeanne Thomassin-Piana, Flora Poizat, Emmanuelle Charafe-Jauffret, Olivier Turrini, Eric Lambaudie, Magali Provansal, Jean-Marc Extra, Anne Madroszyk, Marine Gilabert, Renaud Sabatier, Cécile Vicier, Emilie Mamessier, Christian Chabannon, Jihane Pakradouni, Patrice Viens, Fabrice André, Gwenaelle Gravis, Cornel Popovici, Daniel Birnbaum, Max Chaffanet
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-20 (2021)
Abstract Background The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults with advanced solid can
Externí odkaz:
https://doaj.org/article/685cee8dc4e4477fb464978bcebb91ff
Autor:
Peter Schmid, Marie-Paule Sablin, Jonas Bergh, Seock-Ah Im, Yen-Shen Lu, Noelia Martínez, Patrick Neven, Keun Seok Lee, Serafín Morales, J. Alejandro Pérez-Fidalgo, Douglas Adamson, Anthony Gonçalves, Aleix Prat, Guy Jerusalem, Laura Schlieker, Rosa-Maria Espadero, Thomas Bogenrieder, Dennis Chin-Lun Huang, John Crown, Javier Cortés
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background Xentuzumab—a humanised IgG1 monoclonal antibody—binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by everolimus. This phase Ib/II exploratory trial evaluated xentuzumab plus eve
Externí odkaz:
https://doaj.org/article/1117dc67dd994a8f8f4c31719c73a41f